| 000 | 01796 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515104552.0 | ||
| 264 | 0 | _c20080314 | |
| 008 | 200803s 0 0 eng d | ||
| 022 | _a1468-2079 | ||
| 024 | 7 |
_a10.1136/bjo.2007.123513 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKreutzer, T C | |
| 245 | 0 | 0 |
_aIntravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. _h[electronic resource] |
| 260 |
_bThe British journal of ophthalmology _cMar 2008 |
||
| 300 |
_a351-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFovea Centralis _xpathology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections |
| 650 | 0 | 4 |
_aMacular Edema _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRetinal Vein Occlusion _xcomplications |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVisual Acuity _xdrug effects |
| 650 | 0 | 4 | _aVitreous Body |
| 700 | 1 | _aAlge, C S | |
| 700 | 1 | _aWolf, A H | |
| 700 | 1 | _aKook, D | |
| 700 | 1 | _aBurger, J | |
| 700 | 1 | _aStrauss, R | |
| 700 | 1 | _aKunze, C | |
| 700 | 1 | _aHaritoglou, C | |
| 700 | 1 | _aKampik, A | |
| 700 | 1 | _aPriglinger, S | |
| 773 | 0 |
_tThe British journal of ophthalmology _gvol. 92 _gno. 3 _gp. 351-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bjo.2007.123513 _zAvailable from publisher's website |
| 999 |
_c17719472 _d17719472 |
||